Literature DB >> 27878304

Upregulation of MEK5 by Stat3 promotes breast cancer cell invasion and metastasis.

Fang Liu1, Hao Zhang2, Hui Song1.   

Abstract

Mitogen extracellular-signal-regulated kinase kinase 5 (MEK5) plays an important role in promoting cell proliferation and tumorigenesis. The aberrant expression of MEK5 has been reported in various malignant diseases including cancers of breast, prostate, lung, colorectal and brain. However, the function and regulation of MEK5 signaling pathway are ambiguous and remain elusive with respect to its oncogenic roles in various cancers, especially in the regulation of the initiation and progression of cancer invasion and metastasis. Ectopic expression of MEK5 or knockdown of MEK5 by shRNA with in vitro cell based models demonstrated the role of MEK5 in regulation of epithelial mesenchymal transition (EMT) and breast cancer invasion and metastasis. Here, we show that MEK5 upregulated by Stat3 promotes breast cancer cell invasion through EMT. Further study demonstrated that Stat3 could bind to promoter region of MEK5 and enhanced MEK5 transcription and expression. In addition, the phosphorylation of MEK5 significantly increased in breast cancer cells corresponding to metastatic capability of breast cancer cells. The depletion of MEK5 by shRNA significantly decreased breast cancer invasion. Ectopic expression of MEK5 could confer non-invasive breast cancer cells to become invasion capable cells. Moreover, the phosphorylation of Erk5, a MEK5-regulated downstream kinase, was also upregulated consistent with the increased level of active MEK5. Our studies provide insights into a molecular mechanism by which MEK5 transcriptionally upregulated by Stat3 augments breast cancer cell EMT, which subsequently enhances cancer cell invasion and metastasis. This finding may suggest that Stat3 and MEK5/Erk5 pathways could be an effective therapeutic target for inhibition of breast cancer invasion and metastasis.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27878304     DOI: 10.3892/or.2016.5256

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  16 in total

Review 1.  Oncogenic signaling of MEK5-ERK5.

Authors:  Van T Hoang; Thomas J Yan; Jane E Cavanaugh; Patrick T Flaherty; Barbara S Beckman; Matthew E Burow
Journal:  Cancer Lett       Date:  2017-01-30       Impact factor: 8.679

Review 2.  Breast cancer brain metastasis: molecular mechanisms and directions for treatment.

Authors:  Rute M S M Pedrosa; Dana A Mustafa; Riccardo Soffietti; Johan M Kros
Journal:  Neuro Oncol       Date:  2018-10-09       Impact factor: 12.300

3.  Aberrant MEK5 signalling promotes clear cell renal cell carcinoma development via mTOR activation.

Authors:  Fangzhou Li; Xufeng Peng; Jiale Zhou; Qi Chen; Yonghui Chen
Journal:  J Cancer Res Clin Oncol       Date:  2022-06-17       Impact factor: 4.322

4.  BAY-885, a mitogen-activated protein kinase kinase 5 inhibitor, induces apoptosis by regulating the endoplasmic reticulum stress/Mcl-1/Bim pathway in breast cancer cells.

Authors:  Lei Wang; Xiaochun Ji; Chenxiao Mao; Rui Yu
Journal:  Bioengineered       Date:  2022-05       Impact factor: 6.832

5.  The extracellular-regulated protein kinase 5 (ERK5) enhances metastatic burden in triple-negative breast cancer through focal adhesion protein kinase (FAK)-mediated regulation of cell adhesion.

Authors:  Qiuping Xu; Jingwei Zhang; Brian A Telfer; Hao Zhang; Nisha Ali; Fuhui Chen; Blanca Risa; Adam J Pearson; Wei Zhang; Katherine G Finegan; Ahmet Ucar; Emanuele Giurisato; Cathy Tournier
Journal:  Oncogene       Date:  2021-05-12       Impact factor: 9.867

6.  Benzidine Induces Epithelial-Mesenchymal Transition of Human Bladder Cancer Cells through Activation of ERK5 Pathway.

Authors:  Xin Sun; Tao Zhang; Qifei Deng; Qirui Zhou; Xianchao Sun; Enlai Li; Dexin Yu; Caiyun Zhong
Journal:  Mol Cells       Date:  2018-02-21       Impact factor: 5.034

7.  The MEK5-ERK5 Kinase Axis Controls Lipid Metabolism in Small-Cell Lung Cancer.

Authors:  Sandra Cristea; Garry L Coles; Daniel Hornburg; Maya Gershkovitz; Julia Arand; Siqi Cao; Triparna Sen; Stuart C Williamson; Jun W Kim; Alexandros P Drainas; Andrew He; Laurent Le Cam; Lauren Averett Byers; Michael P Snyder; Kévin Contrepois; Julien Sage
Journal:  Cancer Res       Date:  2020-01-22       Impact factor: 12.701

8.  The novel STAT3 inhibitor WZ-2-033 causes regression of human triple-negative breast cancer and gastric cancer xenografts.

Authors:  Yan Zhong; Lin Deng; Shuo Shi; Qiu-Yao Huang; Shu-Min Ou-Yang; Jian-Shan Mo; Kai Zhu; Xin-Ming Qu; Pei-Qing Liu; Yuan-Xiang Wang; Xiao-Lei Zhang
Journal:  Acta Pharmacol Sin       Date:  2021-07-15       Impact factor: 6.150

Review 9.  Cytokine Signaling in Tumor Progression.

Authors:  Myungmi Lee; Inmoo Rhee
Journal:  Immune Netw       Date:  2017-08-09       Impact factor: 6.303

10.  Phytochemicals inhibit migration of triple negative breast cancer cells by targeting kinase signaling.

Authors:  Pradip Shahi Thakuri; Megha Gupta; Sunil Singh; Ramila Joshi; Eric Glasgow; Alexander Lekan; Seema Agarwal; Gary D Luker; Hossein Tavana
Journal:  BMC Cancer       Date:  2020-01-02       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.